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Abstract
Background: Few studies have taken risk of competing events into account when examining the relationship
between cholesterol and prostate cancer incidence, and few studies have a follow-up over several decades. We
aimed to use these approaches to examine the relationship between cholesterol and prostate cancer.
Methods: A cohort of 1997 healthy Norwegian men aged 40–59 years in 1972–75 was followed throughout 2012.
Cancer data were extracted from the Cancer Registry of Norway. The association between cholesterol and prostate
cancer incidence was assessed using competing risk regression analysis, with adjustment for potential confounders.
Date and cause of death was obtained from the Cause of Death Registry of Norway.
Results: The study cohort had a cancer risk similar to the general Norwegian population. Prostate cancer was
registered in 213 men (11 %), including 62 (3 %) with advanced stage at diagnosis. For overall and advanced stage
prostate cancer, the incidence was twice as high in the lowest quartile of cholesterol compared to the highest
quartile. These associations remained significant after adjustment for age, smoking, physical fitness, BMI, and systolic
blood pressure. Furthermore, high physical fitness and low BMI were associated with increased prostate cancer
incidence. Sensitivity analyses excluding events during the first 20 years of observation revealed similar results.
Conclusion: Low cholesterol, as well as high physical fitness and low BMI, may be associated with increased risk of
prostate cancer. These findings conflict with current prostate cancer prevention recommendations.
Abbreviations: BMI, Body Mass Index (Body Weight/Height2); PSA, Prostate Specific Antigen; SHR, Sub-Hazard
Ratios; SIR, Standardized Incidence Rate
Background
The role of cholesterol and prostate cancer has been a
topic of research for many years. Several observational
studies in the 1980s aroused suspicion of an association
between low cholesterol and increased prostate cancer
risk [1–3]. With notable exceptions [4–7], a majority of
recent studies have pointed to a positive association be-
tween total cholesterol and overall prostate cancer inci-
dence [8–12], or between cholesterol and high-grade
prostate cancer [9, 11–14]. In addition, prostate cancer
mortality has been reported to be higher among those
with initial high cholesterol levels [15], although this
finding is not consistent [16].
From a cell biological point of view, cholesterol may
play an important role in prostate cancer cell growth [17].
A review of a series of reports suggests that use of statins
in cholesterol-lowering therapies may reduce the risk of
aggressive prostate cancer [18]. A possible implication is
that cholesterol-lowering therapies may provide an oppor-
tunity to alter the disease course [19].
However, the role of cholesterol in prostate cancer is
still a challenging research question. Firstly, studies have
not consistently confirmed an association between total
cholesterol and overall or high-grade prostate cancer in-
cidence [4–7]. Secondly, cholesterol is a well-known risk
factor of cardiovascular disease and mortality [20]. Few
studies to date have taken competing events into ac-
count when examining risk of prostate cancer. Using
conventional methods such as the Cox model, deaths
are censored, despite the fact that they may be consid-
ered competing events in the analysis of prostate cancer.
The possibility that this may affect the conclusion of a
study has been demonstrated by Haggström and col-
leagues. In a large longitudinal study that in the first
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case of Cox regression analysis revealed no associations
between metabolic aberrations and prostate cancer risk
[21], they found that men with metabolic aberrations
had lower risk of prostate cancer when competing
events were taken into account [22]. This calls for more
studies assessing the association between cholesterol and
prostate cancer, taking risk of competing events into
account.
Thirdly, the tumor cell proliferation may affect the cir-
culating cholesterol level due to the high metabolic rate
of cancer cells that requires cholesterol esterification
[17]. Thus, a cholesterol-lowering effect of cancer itself
may result in an excess of pre-existing cancer among in-
dividuals with low cholesterol levels. Multiple choles-
terol measures over time have revealed that in some
individuals cholesterol levels may be lower than ex-
pected at as much as 16–18 years before diagnosis,
while in others cholesterol levels decline close to the
time of cancer diagnosis [23]. This emphasizes the
need of restricting analyses to healthy subjects, and
examining results by excluding those who received a
cancer diagnosis through a sufficiently long initial
period of follow-up.
Lastly, screening procedures for prostate cancer may
have influenced incidence rates during the last two
decades and especially increased the proportion of non-
aggressive tumors. The possibility of over-diagnosis actu-
alizes the need to pay special attention to advanced stage
cancer or prostate cancer-specific deaths.
Based on a cohort of initially healthy middle-aged men
followed for 40 years [24–26], we aimed to examine the
relationship between total cholesterol and the incidence
of overall and advanced stage prostate cancer, focusing
on the challenges mentioned above.
Methods
Data sources
The Oslo Ischemia Study; a cohort of working males,
aged 40 to 59 years, recruited from five companies in
Oslo, Norway, in the period 1972–75. They were appar-
ently healthy, free from somatic diseases and not using
drugs. Details about the selection criteria are presented
elsewhere [26, 27]. In total, 2341 employees were invited,
of whom 2014 (86 %) participated by completing the
study protocol.
Information on cancer and cause of death were ob-
tained through linkages between the cohort data, the
Cancer Registry of Norway and the Cause of Death
Registry, respectively. The data were linked through the
unique national identity numbers assigned to every
individual residing in Norway from 1960 onwards. The
Cancer Registry of Norway has registered all cancer
diagnoses nationwide from 1953 onwards. Mandatory
reporting from multiple independent sources ensures
the collection of complete and high quality data [28].
The Cause of Death Registry contains information on all
recorded deaths of Norwegian citizens living in Norway
at time of death since 1951.
Measurements
In accordance with the study protocol, a comprehensive
medical history was taken from all participants in
addition to an extensive physical examination, a chest X-
ray, a panel of fasting blood tests, and a maximal exer-
cise tolerance bicycle test. All participants were asked to
abstain from smoking for at least 8 h, and eating for
12 h, in advance of the examination.
Total serum cholesterol was analyzed by Liebermann
Burchart's no-enzymatic method [29] and divided into
quartiles. Smoking status was categorized as never or
ever smoker. Physical fitness was measured as work cap-
acity (sum of work performed in the bicycle test) divided
by body weight, kJ/kg, and divided into tertiles. Body
mass index (BMI) was calculated based on objectively
measured height and weight (body weight/height2, kg/m2),
and divided into normal weight (BMI < 25) or overweight
(BMI ≥ 25). Resting blood pressure was measured after the
participant had been in the supine position for five mi-
nutes [30], and systolic blood pressure was divided into
quartiles. Participants were encouraged to continue exer-
cising until exhaustion [24]. Age at inclusion was divided
into four groups (<45, 45–49, 50–54, 55+ years).
The cancer data consisted of information on cancer
type (according to the International Classification of
Disease, revision 7), date of diagnosis and stage of dis-
ease at diagnosis. Stage at diagnosis was divided into two
categorises based on information on metastases at diag-
nosis: localized (invasive prostate cancer without any
metastases) and advanced (any infiltration into sur-
rounding structures, regional or distant metastases).
Cases lacking information on metastasis were catego-
rized as “unknown”.
The cohort of men was followed throughout 2012. Of
the 2014 men included, we excluded two men with miss-
ing vital status data and 15 men due to cancer diagnosis
prior to date of the examination. Thus, 1997 men
remained in the cohort for analyses of prostate cancer
incidence. Of these, 1520 men were followed for 20 years
or more. The registrations of baseline variables used in
this study were 100 % complete for all men included.
Statistical analyses
The baseline characteristics are presented as frequencies
and proportions. Comparisons of proportions were
tested by chi-square tests.
Standardized incidence rates (SIR) were computed to
measure the relative risk of cancer (overall and the six
most prevalent sites) in the cohort compared to the
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general male population in the two counties (Oslo and
Akershus) where the men were recruited. Cancer inci-
dences were extracted from the Cancer Registry of
Norway. Reference rates were computed for 5-year age
groups and 3-year calendar periods. Expected numbers
were computed by applying the age- and period-specific
rates to the observed person-years in the cohort. SIRs
were computed by taking the ratio of the observed to ex-
pected incidence, with accompanying 95 % confidence
intervals (CI).
The cohort of men was followed up longitudinally
from the date of examination to the date of diagnosis of
prostate cancer. Cumulative incidence of prostate cancer
was estimated in competing risk models, where death
(all causes) was considered as a competing event. The
men were censored at the date of emigration or study
end (December 31, 2012). Cumulative incidence of pros-
tate cancer, which describes the absolute risk over the
time course, was plotted for each quartile of cholesterol
level. Quartile 1 was compared to quartile 4 by perform-
ing the Pepe and Mori test of equality in cumulative
incidences [31].
To evaluate the effect of cholesterol on prostate cancer
incidence, we performed competing risk regression ana-
lysis with adjustment for potential confounding factors;
age, smoking, physical fitness, BMI, and systolic blood
pressure (all categorical as given above). We used the
Fine and Gray model [32], which extends the Cox pro-
portional hazards model to competing risks data by con-
sidering the sub-distribution hazard while adjusting for
the competing risk of (all cause) death. The strength of
the association between each variable and the outcome
was assessed using the sub-hazard ratios (SHR). Tests
for trend across categories were performed by entering
categorical variables as continuous in the models. The
model assumptions were found to be adequately met
and no significant interactions were observed.
We conducted sensitivity analyses restricted to men
who were still alive and free from prostate-cancer at
20 years of follow-up, and followed them for the next
20 years. Further, we performed separate analyses for lo-
calized and advanced stage prostate cancer. In the stage-
specific analysis, diagnosis at the other stage was defined
as a competing event (i.e., localized stage prostate cancer
was considered a competing event when studying
advanced stage prostate cancer). For comparison, we
conducted Cox regression analysis equivalent to the
competing risk regression analysis of prostate cancer in-
cidence. Results from the Cox analyses are presented as
supplementary files.
Among men diagnosed with prostate cancer, we per-
formed a separate competing risk analysis to evaluate
the effect of cholesterol on prostate cancer death. The
method of Fine and Gray was used to analyze time to
prostate cancer specific death with death from other
causes as a competing event.
All statistical analyses were performed using Stata
[33]. In particular, we used the stcrreg and stcompet
modules when analyzing competing events.
Results
During the 40 years observation period 1511 men died
(all causes) and 758 were diagnosed with cancer.
Prostate cancer was registered in 213 men, of which
137 were localized, 62 advanced and 14 with an un-
known stage at time of diagnosis (Fig. 1). The cancer
risk in the study cohort was not different from the
cancer risk in the general population (Table 1).
Higher cholesterol was associated with higher age,
lower fitness, and higher blood pressure (Table 2).
Smoking prevalence and BMI were not significantly
associated with cholesterol level.
When using competing risk regression to study the as-
sociation between cholesterol and risk of prostate cancer
(Table 3) the incidence rate was found to be significantly
Fig. 1 Flowchart of the cohort of initially healthy 40 to 59 year old
men recruited in the period 1972–75 and followed for 40 years, Oslo
Ischemia Study
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higher in cholesterol quartile 1 compared to quartile 4
(SHR 2.2, 95 % CI 1.4 – 3.2). This difference remained
significant when adjusting for age, smoking, physical
fitness, BMI, and systolic blood pressure. In addition,
the incidence rate was found to be significantly higher
among men who had the highest physical fitness level
(tertile 3) compared to men in the lowest level (tertile 1)
(SHR 1.7, 95 % CI 1.1-2.5), and lower in men with
BMI ≥25 compared to men with BMI <25 (SHR 0.69,
95 % CI 0.52–0.93) (Table 3). The effects of the co-
variates on the cause-specific hazard from the Cox
analysis were of the same magnitude (Additional file 1:
Table S1). Figure 2 shows the variation in cumulative
incidence of prostate cancer by quartiles of choles-
terol. Compared to quartile 4, men in quartile 1 had
significantly higher risk of prostate cancer after 40 years of
follow-up.
Results from sensitivity analyses restricted to men
who were still alive and free from prostate cancer at
20 years of follow-up (Fig. 3) show similar results as
those obtained for full-time follow-up (Fig. 2 and
Table 3).
Localized stage prostate cancer was not associated
with cholesterol levels (Fig. 4a), while results for ad-
vanced stage cancer (Fig. 4b) confirmed the overall re-
sult of increased risk of prostate cancer in the first
quartile as compared to the fourth quartile of choles-
terol. However, the fully adjusted Fine and Gray compet-
ing risk models demonstrated an association between
cholesterol and prostate cancer incidence for both stages
(Additional file 1: Table S2A), and advanced stage
cancer and prostate cancer-specific death in combined
(Additional file 1: Table S2B).
Among men diagnosed with prostate cancer, 81 (38 %)
died of the disease with mean age at death 79.5 years
(Additional file 1: Table S3). No associations were ob-
served between cholesterol (and the other covariates)
and risk of prostate cancer-specific death (Additional
file 1: Table S4 and Figure S1).
Discussion
In this cohort of initially healthy middle-aged men, we
found a negative association between baseline cholesterol
levels and the incidence of prostate cancer. The finding is
in contrast to the majority of studies in this field, which
Table 1 Standardized incidence rates (SIR) analysis with 95 %
confidence intervals (CI) for cancer (overall and the six most
prevalent sites) in the cohort compared to the general male
population in Oslo and Akershus
Observed Expected SIR (95 % CI)
Cancer, overall 758 798.3 0.95 (0.88–1.02)
Colon 87 81.9 1.06 (0.86–1.31)
Rectum 44 47.4 0.93 (0.69–1.25)
Lung 109 126.0 0.86 (0.72–1.04)
Prostate 213 201.7 1.06 (0.92–1.21)
Bladder and kidney 104 100.7 1.03 (0.85–1.25)
Melanoma 94 83.7 1.12 (0.92–1.37)
Table 2 Baseline characteristics stratified by quartiles of cholesterol (numbers and proportions) in the cohort of healthy middle-aged
men, n = 1997
Cholesterol (mmol/l)
Total Q1 (2.7–5.8) Q2 (5.9–6.6) Q3 (6.7–7.4) Q4 (7.5–15.4) P-value
Age at inclusion (years) <45 469 (23.5) 155 (29.0) 130 (24.9) 103 (21.8) 81 (17.3) <0.001
45–49 568 (28.5) 154 (28.8) 158 (30.3) 127 (26.9) 129 (27.5)
50–54 550 (27.5) 126 (23.6) 147 (28.2) 139 (29.5) 138 (29.4)
55+ 410 (20.5) 99 (18.5) 87 (16.7) 103 (21.8) 121 (25.8)
Smoking Ever 1495 (74.9) 386 (72.3) 389 (74.5) 351 (74.4) 369 (78.7) 0.13
Never 502 (25.1) 148 (27.7) 133 (25.5) 121 (25.6) 100 (21.3)
Physical fitness (kJ/kg) T1 (21.1–118.6) 666 (33.4) 148 (27.7) 172 (33.0) 165 (35.0) 181 (38.6) <0.001
T2 (118.7–161.2) 666 (33.4) 164 (30.7) 163 (31.2) 161 (34.1) 178 (38.0)
T3 (161.3–514.9) 665 (33.2) 222 (41.6) 187 (35.8) 146 (30.9) 110 (23.5)
Body mass index (kg/m2) <25 1209 (60.5) 335 (62.7) 324 (62.1) 286 (60.6) 264 (56.3) 0.16
≥25 788 (39.5) 199 (27.3) 198 (37.9) 186 (39.4) 205 (43.7)
Systolic blood pressure (mmHg) Q1 (88–118) 578 (28.9) 181 (33.9) 166 (31.8) 132 (28.0) 99 (21.1) <0.001
Q2 (120–128) 484 (24.2) 150 (28.1) 122 (23.4) 96 (20.3) 116 (24.7)
Q3 (130–140) 457 (22.9) 99 (18.5) 119 (22.8) 114 (24.2) 125 (26.7)
Q4 (142–220) 478 (23.9) 104 (19.5) 115 (22.0) 130 (27.5) 129 (27.5)
T1 - T3: tertiles 1 to 3, Q1 - Q4: quartiles 1 to 4
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have pointed to a positive relationship between cholesterol
and incidences of overall prostate cancer [8–12] or ad-
vanced stage prostate cancer [9, 11–14].
We consider it important to report this contradiction
for several reasons. Firstly, we have taken risk of com-
peting events into account when analyzing the associ-
ation between cholesterol level and prostate cancer.
Since cholesterol is a well-known risk factor of cardio-
vascular disease and mortality [20], statistical procedures
in which deaths are censored may lead to biased conclu-
sions [34]. Among the above-cited studies that have used
a prospective longitudinal design [9, 10, 12–14], none
included competing risk analyses. Among prospective
studies that have found no associations between choles-
terol and prostate cancer risk [4–7], only the study by
van Hemelrijck et al. [4] has performed competing risk
analyses.
Secondly, the long follow-up in our study made it pos-
sible to conduct an additional analysis in which we ex-
cluded all deaths and prostate cancer cases occurring
during the first 20 years of observation. Results similar
to those obtained without excluding data reduce the
likelihood of reversed causality due to the possibility that
early stages of prostate cancer may affect baseline levels
of cholesterol.
Moreover, we observed that both high physical fit-
ness and low BMI were independently associated with
the risk of prostate cancer. Based on the most au-
thoritative scientific research worldwide, the relation-
ship between physical activity and prostate cancer is
inconclusive [35]. However, the majority of these
studies are based on self-reported levels of physical
activity and, as far as we know, no studies have re-
ported the relationship between measured physical
Table 3 Competing risk regression to evaluate the effect of selected covariates on prostate cancer incidence
Full-time follow-up period, n = 1997 Restricted to more than 20 year of follow-up, n = 1520
Univariate analyses Multivariate analysis Multivariate analysis
SHR (95 % CI) P-value SHR (95 % CI) P-value SHR (95 % CI) P-value
Cholesterol (mmol/l) <0.001* <0.001* 0.01*
Q1 (2.7 – 5.8) 2.15 (1.44–3.22) <0.001 2.00 (1.32–3.03) 0.001 2.00 (1.20–3.34) <0.01
(5.9 – 6.6) 1.36 (0.88–2.09) 0.17 1.29 (0.83–2.00) 0.26 1.46 (0.86–2.48) 0.16
Q3 (6.7 – 7.4) 1.42 (0.92–2.21) 0.12 1.36 (0.87–2.12) 0.17 1.55 (0.90–2.66) 0.11
Q4 (7.5 – 15.4) 1 1 1
Age at inclusion (years) 0.48* 0.40* 0.36*
< 45 1 1 1
45–49 0.84 (0.58–1.20) 0.33 0.92 (0.64–1.32) 0.66 0.97 (0.66–1.43) 0.89
50–54 0.87 (0.60–1.25) 0.45 1.09 (0.73–1.62) 0.67 0.86 (0.54–1.35) 0.51
55+ 0.85 (0.57–1.27) 0.43 1.15 (0.75–1.79) 0.52 0.80 (0.46–1.40) 0.44
Smoking
Never 1 1 1
Ever 0.75 (0.56–1.01) 0.06 0.79 (0.59–1.07) 0.12 0.81 (0.58–1.14) 0.22
Physical fitness (kJ/kg) <0.001* 0.01* 0.12*
T1 (21.1 – 118.6) 1 1 1
T2 (118.7 – 161.2) 1.38 (0.96–1.98) 0.08 1.43 (0.98–2.07) 0.06 1.27 (0.82–1.99) 0.29
T3 (161.3 – 515.9) 1.76 (1.25–2.48) <0.01 1.68 (1.14–2.47) 0.01 1.43 (0.92–2.22) 0.11
Body mass index (kg/m2)
<25 1 1 1
≥ 25 0.66 (0.49–0.89) <0.01 0.69 (0.52–0.93) 0.01 0.62 (0.44–0.88) <0.01
Systolic blood pressure (mmHg) 0.59* 0.55* 0.41*
Q1 (88 – 118) 1 1 1
Q2 (120 – 128) 0.85 (0.59–1.23) 0.39 0.89 (0.62–1.28) 0.53 1.00 (0.66–1.51) 0.99
Q3 (130 – 140) 0.83 (0.57–1.22) 0.35 0.96 (0.65–1.40) 0.83 1.06 (0.68–1.65) 0.79
Q4 (142 – 220) 0.92 (0.64–1.32) 0.63 1.13 (0.78–1.65) 0.52 1.22 (0.78–1.93) 0.37
SHR sub-distribution hazard ratios, CI confidence interval, Q1 - Q4 quartiles, T1 - T3 tertiles
*P-value from test for trend across ordered categories
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Fig. 2 Cumulative incidence of prostate cancer by quartiles of cholesterol in a cohort of initially healthy middle-aged men followed for 40 years,
n = 1997. The number of prostate cancer diagnosis in each quartile of cholesterol was 80 (quartile 1), 51 (quartile 2), 48 (quartile 3) and 34 (quartile 4).
P-value achieved from the Pepe and Mori test comparing the cumulative incidence of cholesterol quartile 1 versus quartile 4
Fig. 3 Cumulative incidence of prostate cancer by quartiles of cholesterol restricted to men with 20 years or more follow-up time, n = 1520. The
number of prostate cancer diagnosis in each quartile of cholesterol was 60 (quartile 1), 42 (quartile 2), 36 (quartile 3) and 21 (quartile 4). P-value
achieved from the Pepe and Mori test comparing the cumulative incidence of cholesterol quartile 1 versus quartile 4
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fitness and risk of prostate cancer in a similar way to
that presented here. Similarly, the relationship be-
tween overweight or obesity and risk of prostate cancer is
inconclusive, although the evidence is considered to be
strong for a relationship between high BMI and risk of
advanced stage disease [35].
It is important to consider the possibility that screen-
ing procedures for prostate cancer may have influenced
our findings [18]. Testing for Prostate Specific Antigen
(PSA) has since the early 1990s strongly influenced the
incidence rates of prostate cancer and especially in-
creased the proportion of non-aggressive tumors.
Individuals who have an increased awareness of health,
or belong to a social environment with more attention
to disease prevention, may have lower cholesterol levels
and simultaneously be more likely to attend tests for
prostate cancer. This may explain the association be-
tween lower cholesterol levels and higher prostate can-
cer incidence. However, this hypothesis would primarily
apply to the relationship between cholesterol and local-
ized stage cancer and be less relevant for advanced stage
cancer. In the present study, the association between
cholesterol levels and incidence of localized stage pros-
tate cancer was weaker than the association between
Fig. 4 Cumulative incidence of a localized and b advanced stage prostate cancer by quartiles of cholesterol. The number of localized prostate
cancer cases in quartiles of cholesterol was 48, 33, 33, 23, respectively, and the number of advanced prostate cancer cases was 24, 14, 15, 9,
accordingly. P-values achieved from the Pepe and Mori test comparing the cumulative incidence of cholesterol quartile 1 versus quartile 4. Fully
adjusted Fine and Gray competing risk model is presented in Additional file 1: Table S2A
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cholesterol levels and advanced stage cancer, which re-
duces the likelihood of a biased selection to prostate
cancer screening tests as a possible explanation of the
association. Furthermore, testing for PSA received no
application of importance in Norway until the mid-
1990s. The proportion of person-years in the study co-
hort which was in the target group for PSA testing
(≤70 years) after 1995, was less than 6 %. Thus, PSA
testing had minimal impact on the findings in the
present study.
Prospective studies assessing the association between
baseline cholesterol and prostate cancer incidence will
generally be vulnerable to substantial changes in lipid
metabolism during follow-up. Some participants might
have developed hypercholesterolemia during the obser-
vation period. Further, some participants with high chol-
esterol levels might have received medical treatment. In
Norway, statins have been available for prescription use
since the early 1990-ies, and the cholesterol-lowering ef-
fect of statins may have influenced our results. However,
changes in cholesterol levels can in general be seen as
regression to the mean and will largely serve to reduce
the strength of the estimated associations.
Another limitation is lack of data on cellular atypia or
glandular architecture [36] which may serve as powerful
prognostic factors for prostate cancer. In the present
study stage at diagnosis was restricted to two categories,
localized cancer defined as invasive cancer without me-
tastases, and advanced prostate cancer with infiltration
into surrounding structures or metastases.
Strengths of our study include that it is among the
longest and most complete follow-up studies of initially
working and healthy middle-aged men. Similar cancer
incidences as in the general population indicate high ex-
ternal validity for Caucasian populations in high income
countries. Cholesterol levels were determined by stan-
dardized methods. Physical fitness was measured by an
exercise test, as opposed to self-reports of physical activ-
ity typically used in epidemiological studies that may
underestimate the association between physical activity
and health outcomes [37]. By using physical examina-
tions to measure height and weight we also eliminated a
risk of error and response biases that is associated with
self-reported height and weight [38].
Conclusions
Low cholesterol, as well as high physical fitness and low
BMI, may be associated with increased risk of prostate
cancer. The relationship applies even to advanced stage
cancer, which to a less extent is influenced by PSA test-
ing. These findings are contrary to the advice about
healthy lifestyle in the prevention of prostate cancer and
may be important in the discussion on whether choles-
terol affects the risk of prostate cancer.
Additional file
Additional file 1: Table S1. Cox regression to evaluate the effect of
selected covariates on prostate cancer incidence ignoring death as
competing event (treated as censored), n = 1997. Table S2A. Cox and
competing risk regression to evaluate the effect of selected covariates on
(a) localized and (b) advanced stage prostate cancer incidence. N = 1997,
whereof 137 localized and 62 advanced stage prostate cancer cases.
Table S2B. Cox and competing risk regression to evaluate the effect of
selected covariates on advanced stage prostate cancer incidence and
prostate cancer-specific death in combined. N = 1997, whereof 105 events
(62 advanced stage prostate cancer cases and 43 deaths of prostate
cancer). Table S3. Number and age of death stratified by quartiles of
cholesterol, Oslo Ischemia Study. Table S4. Competing risk regression to
evaluate the effect of selected covariates on prostate cancer-specific
death in men diagnosed with prostate cancer. 213 men were diagnosed
with prostate cancer, whereof 81 died of prostate cancer (failure), 82 died
of other causes (competing event), and 50 were alive at end of follow-up
(censored). Figure S1. Cumulative incidence of prostate cancer death by
quartiles of cholesterol in men diagnosed with prostate cancer, n = 213.
Death of other causes was considered as competing events. P-value
achieved from the Pepe and Mori test comparing the cumulative
incidence of cholesterol quartile 1 versus quartile 4. (DOC 147 kb)
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